Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

The normal plasma protein serum amyloid P component (SAP) binds to fibrils in all types of amyloid deposits, and contributes to the pathogenesis of amyloidosis. In order to intervene in this process we have developed a drug, R-1-[6-[R-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-carboxyli...

Full description

Bibliographic Details
Main Authors: Pepys, M.B (Author), Herbert, J. (Author), Huchinson, W.L (Author), Tennent, G.A (Author), Lachmann, H.J (Author), Gallimore, J.R (Author), Lovat, L.B (Author), Bartfai, T. (Author), Alanine, A. (Author), Hertel, C. (Author), Hoffman, T. (Author), Jakob-Roetne, R. (Author), Norcross, R.D (Author), Kemp, J.A (Author), Yamamura, K. (Author), Suzuki, M. (Author), Taylor, G.W (Author), Murray, S. (Author), Thompson, D. (Author), Purvis, A. (Author), Kolstoe, S. (Author), Wood, S.P (Author), Hawkins, P.N (Author)
Format: Article
Language:English
Published: 2002-05-16.
Subjects:
Article
Online Access:Get fulltext

Internet

Get fulltext

Similar Items